C yclosporin A (CsA) is not a benign drug, and its use for immunosuppression in insulin-dependent diabetes mellitus (IDDM) of recent onset in humans remains controversial (1,2). The effect of systematically administrated CsA on residual insulin secretion in some patients tends to decrease with time and disappears on discontinuation of the drug. The effect is ob-
C yclosporin A (CsA) is not a benign drug, and its use for immunosuppression in insulin-dependent diabetes mellitus (IDDM) of recent onset in humans remains controversial (1, 2) . The effect of systematically administrated CsA on residual insulin secretion in some patients tends to decrease with time and disappears on discontinuation of the drug. The effect is ob-tainable only with concentrations of CsA associated with toxic effects including kidney and liver damage, hypertension, hypertrichosis and gum hypertrophy, mandibular prognathism, acne, pilar keratosis, and hirsutism (3, 4) .
The spontaneous onset of diabetes in the NOD mouse is similar to human IDDM in both genetics and autoimmune pathogenesis (5) . Because interleukin 2 (IL-2) deficiency and related suppressor cell dysfunction may be important in this autoimmune disorder (6) (7) (8) , we investigated a novel strategy to induce specific immunosuppression based on the hypothesis that specific suppressor cell activity can be increased by IL-2 if cytolytic/helper activities are simultaneously blocked by CsA. Because a characteristic of nonobese diabetic (NOD) mice is an unusually high percentage of splenic T-lymphocytes (9), splenic lymphoid cells from young not-yet-diabetic female NOD mice were exposed ex vivo to IL-2 plus CsA for 72 h before their injection into the same animal from which they were isolated. Frequency of diabetes was estimated 19 wk later at 31 wk of age.
MATERIALS AND METHODS
The Sansum NOD mouse colony was established in 1985 from five breeding pairs obtained from Clea Japan by brothersister inbreeding. IDDM is first observed among the female mice at about 12 wk of age, and thereafter the number of mice with overt diabetes increases. The cumulative incidence reaches 80-85% at 26 wk of age. Diabetes occurs in few males (<10% at the age of 30 wk). Forty-nine female NOD mice aged 12 wk and not yet diabetic were randomly allocated into five groups with 5-21 mice per group. The group of 21 untreated female NOD mice were controls (group 5). In four experimental groups (groups 1-4), splenectomy was performed aseptically followed by ligation of the splenic artery and vein and suture of the peritoneum parietale. Splenic lymphoid cells from individual mice were isolated from the interphase of the Ficoll-Hypaque gradient and suspended in RPMI-1640 medium supplemented with 10 mM HEPES (pH 7.4), 15% Hyclone fetal calf serum, 1% L-glutamine, 1% antibiotic mixture (PSN, Gibco, Grand Island, NY) with 7) no fAge-matched female NOD control mice not treated in any way. addition, 2) 1 (xg CsA (Sandoz, East Hanover, NJ)/ml, 3) 100 U recombinant IL-2 (Amgen, Thousand Oaks, CA)/ml, or 4) 100 U recombinant IL-2 plus 1 |xg CsA/ml. Cells from individual mice were incubated at 2 x 10 6 cells/ml in 24-well culture plates for 72 h at 37°C in a gaseous phase of humidified air/5% CO 2 . After culture the cells were thoroughly washed in balanced salt solution and injected (~4 -9 x 10 7 cells/mouse) intraperitoneally into the original donor. Each mouse was caged alone. Flow-cytometric analysis. In a series of additional experiments, splenic lymphoid cells isolated from female NOD mice, reaching on average 12 wk of age and not yet diabetic, were cultured for 72 h in one of the four media as described. The cells were then washed with phosphate-buffered saline with 2% fetal calf serum and 0.1% azide and incubated in 50 |xl FITC-conjugated monoclonal antibody L3T4 or Lyt2 (Beckton Dickinson, Mountain View, CA). Cells (10 4 ) were analyzed by use of a fluorescence-activated cell sorter (FACscan). Dead cells were gated out of the analysis, and the percentage distribution and ratio of L3T4 to Lyt2 phenotype cells were determined. Disease detection. Acute onset of diabetes was defined as the development of polyuria, glucosuria, and elevated random postprandial plasma glucose levels (>500 mg/dl). Blood was obtained from the retro-orbital sinus, and glucose levels were documented by a glucose oxidase method (Beckman glucose analyzer). Pathology. For histological examination, pancreases were quickly removed, and sections were fixed in buffered formalin, stained with hematoxylin and eosin, and read doubleblind by two observers. The extent of lymphocytic infiltration (intensity of diabetic insulitis) in an islet was scored 0-3, with 0 indicating normal islet morphology and absence of insulitis, 1 <25%, 2 <50%, and 3 >50% histological alterations. The grade of insulitis in a mouse was expressed as the average score calculated by total score divided by number of islets. Approximately 30 islets in different sections were examined per pancreas. Statistical analysis. The number of overtly diabetic mice were counted in each group treated in the same way. Statistical analysis of 2 x 2 tables was performed with the x 2 -statistic (df = 1) to quantitate differences in the incidence of diabetes between groups.
RESULTS
Incidence of diabetes. Table 1 shows that 86% (18 of 21) of the selected control mice in the control group developed diabetes between age 12 and 31 wk. Only 18% (2 of 11) of the mice reinfused with their own splenic lymphoid cells cultured with CsA plus IL-2 developed diabetes after 31 wk of life. The two mice that developed diabetes at the initiation of the immunotherapy probably already had a reduced pcell mass, and thus the attempt to preserve sufficient insulin secretory function was ineffective. Data from the three experimental groups in Table 1 show that 80-100% of the mice developed diabetes between age 12 and 31 wk.
IL-2 induced an increase in the Lyt2 T-lymphocyte subpopulation concomitant with a reduction in the ratio of L3T4-to Lyt2-phenotype T-lymphocytes (Table 2) . Thus, IL-2 can drive a clonal expansion of Lyt2 T-lymphocytes that is not affected by the presence of CsA. The data in Table 2 indicate that IL-2 plus CsA at least partly mediates the effect by a direct action on cells of the Lyt2 phenotype lineage, i.e., cytotoxic/suppressor cells. Pathology. Sections of pancreases from three 31-wk-old normoglycemic mice in group 4 examined by light microscopy showed that most of the islets were normal and free from lymphocytic infiltration (Fig. 1) . Mild degrees of lymphocytic infiltration were observed in the rest of the islets, indicating that progress to islet destruction had occurred but appeared abrogated. A typical histological appearance of the pancreas from a 12-wk-old not-yet-diabetic female NOD mouse is shown in Fig. 2 . A mildly lymphocytic infiltration indicates the progression to islet destruction. Sections of the pancreases of mice in groups 1-3 and the control group, killed after onset of glucosuria, showed intense lymphocytic infiltration in virtually all of the islets by light microscopy, in Splenich lymphoid cells were isolated and cultured as described in MATERIALS AND METHODS. Values are mean of 3 individual 12-wk-old not-yet-diabetic female NOD mice ± SD. *P value vs. no additive. •\, .
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FIG. 2. Typical appearance of islets in normoglycemic 12
-wk-old female NOD mice. Mildly lymphocytic infiltration is seen in 1 islet. Hematoxylin and eosin, x100. fRandomly selected from the Sansum/NOD mouse colony.
agreement with the diabetic status of these animals. Table  3 shows the various grades of diabetic insulitis.
DISCUSSION
There are striking similarities between the pathogenesis of diabetes in the NOD mouse and the human disease: 1) the autoimmune-mediated islet cell destruction is a slow and prolonged process with a relatively long period from the initial triggering event to the appearance of overt disease (10,11); 2) the lymphocytic infiltrate confined to the islets is associated with a determinant encoded in MHC class II genes (12,13); 3) the disease can be passively transferred by lymphocytes from diabetic into nondiabetic syngeneic recipients (14,15); 4) there is deficiency in IL-2 production and related dysfunction of suppressor cell activity (6-8); and 5) the disease is susceptible to immunosuppressive agents such as CsA (2, 16) . Our data demonstrate that onset of diabetes can be suppressed in the diabetic-prone but not-yet-diabetic female NOD mouse by the activity governed by its own splenic lymphoid cells after ex vivo exposure to CsA plus IL-2 for 72 h.
What mechanism induces this suppressor cell activity? In vitro studies have demonstrated that CsA effectively blocks the activity of cytolytic helper T-lymphocytes but fails to block the activity of suppressor T-lymphocytes (17) . IL-2 is a Tlymphocyte growth factor and is required to stimulate the proliferation of suppressor T-lymphocytes, but IL-2 has no reported effect on either cytolytic or helper T-lymphocytes when blocked by CsA (18) . Thus, it appears from the in vitro studies cited that cytolytic T-lymphocyte activity is consistently suppressed when CsA plus IL-2 is present, but suppressor activity remains or is augmented. Augmentation of suppressor cells seems probable in our experiments because group 2 animals (CsA exposure) and group 3 animals (IL-2 exposure) showed high incidence rates for diabetes, indicating that decreasing helper T-lymphocyte activity is not sufficient in itself to prevent diabetes under the conditions of the experiment.
The flow cytometric data presented herein show that IL-2 induces proliferation of the Lyt2 T-lymphocyte subpopulation. A greater potency in augmenting the generation of suppressor T-lymphocytes by IL-2 obviously occurred when CsA was present, as supported by our in vivo observations of increased suppressor activity. Further experiments with Tlymphocyte-enriched preparations should elucidate the relationship between IL-2 and CsA in terms of the T-lymphocyte subpopulation they stimulate. The autologous suppressor cells in our studies were created in the absence of an appropriate antigenic stimulus. Whether the suppressor activity is anti-idiotypic with specificity for the idiotypes carried by activated T-lymphocytes is unknown, but such anti-idiotypic cells could function as suppressors (19) .
How do our observations relate to IDDM in humans? Over 50% of the inherited predisposition to IDDM maps to the region of chromosome 6 that contains the highly polymorphic MHC class II genes that determine immune responsiveness. Thus, the alleles of HLA-DQp determine disease susceptibility (13) . If individuals with DNA or other markers that segregate with IDDM can be detected before islet destruction occurs, autologous suppressor cells prepared as described herein could prophylactically halt the development of this autoimmune disease in individuals with minimal risk. Finally, adoptive immunotherapy may have implications for other autoimmune diseases, e.g., rheumatoid arthritis and pemphigus vulgaris (20) .
